There was no conference call held by BioSante Pharma $BPAX in connection with the 2q-2012 earnings release, but a couple quick notes from their quarterly SEC filing:
- cash until 3q-2013
- new LibiGel phase 3 trials to start mid-2013. Combined spend of $30-36m over 18 months
- now $8.3m notes out as of 7/31
- phase 2 of gvax melanoma + revlimid is enrolling, target 15 pts
- Libigel safety study next interim look 3q-2012, top-line unblinded data in 4q-2012
RSS Feed
